Collectively, our mutation profiling underscores that although the overall mutational spectrum remains largely conserved between high- and low-risk groups, subtle variations—particularly in APC mutation frequency and the interplay with TMB—may underlie the biological heterogeneity and differential prognosis in COAD patients. The gene discussed is APC; the disease is colon adenocarcinoma.